Peptyde Bio, a St. Louis-based agriculture technology startup developing natural fungicides, has been acquired by a firm located just outside Boston.

Cambridge, Massachusetts-based Invaio Sciences said Thursday it has acquired Peptyde Bio, which was spun out of research at the Donald Danforth Plant Science Center in Creve Coeur. Financial terms of the deal were not disclosed.

The acquisition marks the first startup exit for the Danforth Technology Co. (DTC), a subsidiary of the Danforth Center focused on helping Danforth Center scientists commercialize their research and technology. DTC launched in 2022, and Peptyde Bio was the first startup it established.

“This is a really strong validation of the model,” said Tom Laurita, who is CEO of DTC and has served as CEO of Peptyde Bio.

“This acquisition adds Peptyde Bio’s portfolio of confirmed peptide lead candidates for use in crop protection to our existing pipeline. When combined with our innovative biological delivery systems, we are uniquely positioned to offer growers more natural, efficient and effective solutions to protect their crops,” Ignacio Martinez, founding CEO of Invaio, said in a news release. READ MORE